MN-029 (denibulin HCl) is a novel vascular-disrupting agent that reversibly inhibits microtubule assembly, resulting in disruption of the cytoskeleton of tumor vascular endothelial cells. This study determined the safety, pharmacokinetics, and acute anti-vascular effects of MN-029.

PURPOSE: MN-221 is a novel, highly selective β2 agonist in development for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). MN-221 has a greater selectivity for the human β2 receptors than commonly used β2 agonists (i.e., albuterol, levalbuterol, terbutaline). MN-221 has been studied in both stable asthmatics and in acute exacerbations of asthma with results indicating increased effects on FEV1 and minimal effects of heart rate and blood pressure. A 1-hour infusion has produced a markedly greater improvement in FEV1 than the 2-hour regimen ion stable asthmatics.